Reata Pharmaceuticals

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Company Growth (employees)
Type
Public
HQ
Irving, US
Founded
2002
Size (employees)
75 (est)+18%
Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US

Key People at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has an office in Irving
Irving, US (HQ)
150 2801 Gateway Dr

Reata Pharmaceuticals Data and Metrics

Reata Pharmaceuticals Financial Metrics

Reata Pharmaceuticals's revenue was reported to be $49.9 m in FY, 2016 which is a 1% decrease from the previous period.
USD

Revenue (FY, 2016)

49.9 m

Revenue growth (FY, 2015 - FY, 2016), %

(1%)

Net income (FY, 2016)

(6.2 m)

Market capitalization (18-Aug-2017)

588 m

Cash (31-Mar-2017)

82.7 m
Reata Pharmaceuticals's current market capitalization is $588 m.
USDFY, 2015FY, 2016

Revenue

50.3 m49.9 m

Revenue growth, %

(1%)

R&D expense

35.1 m39.5 m

General and administrative expense

13.7 m16.6 m

Operating expense total

50.7 m56.7 m

Pre tax profit

(302 k)(6.7 m)

Income tax expense

1.1 m(441 k)

Net Income

(1.5 m)(6.2 m)
USDFY, 2015FY, 2016

Cash

42 m84.7 m

Inventories

2.6 m

Current Assets

77.3 m87.3 m

PP&E

1.1 m819 k

Total Assets

80 m89.1 m

Accounts Payable

3.8 m

Current Liabilities

60.8 m59.6 m

Non-Current Liabilities

291.3 m244.5 m

Total Liabilities

352.1 m304.1 m

Additional Paid-in Capital

10 m74.3 m

Retained Earnings

(283.1 m)(289.4 m)

Total Equity

(273.2 m)(215 m)

Financial Leverage

-0.3 x-0.4 x
USDQ2, 2016Q3, 2016Q1, 2017

Cash

92.4 m95.7 m82.7 m

Current Assets

112.9 m99.9 m85.7 m

PP&E

942 k899 k703 k

Total Assets

114.4 m101.8 m88.2 m

Accounts Payable

1.6 m1.3 m541 k

Current Liabilities

60 m60.1 m51.2 m

Non-Current Liabilities

266.6 m254 m257.3 m

Additional Paid-in Capital

72.2 m73 m76.3 m

Retained Earnings

(284.3 m)(285.2 m)(296.6 m)
USDFY, 2015FY, 2016

Net Income

(1.5 m)(6.2 m)

Depreciation and Amortization

1.8 m682 k

Inventories

(1.2 m)

Accounts Payable

299 k

Cash From Operating Activities

(44.6 m)(19.3 m)

Purchases of PP&E

(272 k)(340 k)

Cash From Investing Activities

(260 k)(339 k)

Cash From Financing Activities

(870 k)62.3 m

Income Taxes Paid

1.2 m

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Phase III Trials

1

Phase II Trials

4

Phase I Trials

2

Patents Pending

280

Reata Pharmaceuticals Market Value History

Traffic Overview of Reata Pharmaceuticals

Reata Pharmaceuticals Online and Social Media Presence

Reata Pharmaceuticals Company Life and Culture

You may also be interested in